Table SI. *Clinical characteristics, severity, treatment schedules, efficacy and outcome in infliximab-treated patients with hidradenitis suppurativa*

Year (Ref.)	No. patients (Male/ Female)	No. of areas involved*	Severity	Smoke Yes/No	Associated co-morbidity Yes/No	No. of infusions (mean)/ Mean treatment duration	Associated therapy	Response during treatment Yes/No	Induction/ continuous therapy	Mean follow-up time/outcome
2003 (1)	5 (1M/4F)	A=2 B=3	Severe (5)	NA	NA	1.6/ NA	Prednisone: 2 Cyclosporine: 1	Yes: 5	Induction: 5	NA/NA
2007 (5)	7 (4M/3F)	A=7 B=0	Severe (7)	NA	NA	3.7/10.6 weeks	No	Yes: 5 No: 2	Induction: 7	NA/SAE: 4 Recurrence: 1 after 10 weeks, NA: 2
2007 (3)	4 (2M/2F)	A=1 B=3	Severe (4)	NA	1/3	4.5/15 weeks	NA	Yes: 2 No: 2	Induction: 3 Continuous: 1	42.3 weeks/ Suspen. SAE: 2 NA: 1 pt.
2007 (6)	3 (3F)	A=2 B=1	Moderate (2) Severe (1)	NA	1/2	6.7/35.3 weeks	NA	Yes: 2 No: 1	Induction: 1 Continuous: 2	40.7 weeks/ Loss of response: 1 Suspen. SAE: 1
2007 (1)	6 (2M/4F)	A=1 B=5	Severe (6)	NA	1/5	NA/NA	No	Yes: 6	Continuous: 6	24 weeks/ Loss of response: 3 Stable while on therapy: 3
2008 (1)	11(4M/6F) 1 NA	NA Sartorius Index[1]	Severe (11)	10/1 NA	NA	3/6 weeks	No	Yes: 10 NA: 1	Induction: 11	54 weeks SAE: 3 Recurrence: 8 (average time: 8.5 months)
2007 (7)	3 (1M/2F)	A=0 B=3	Severe (3)	NA	2/1	6.3/26.7 weeks	Minocycline: 2	Yes: 3	Continuous until remission: 3	48.7 weeks Stable: 1 (46 weeks) Recurrence: 2 after 24 and 12 weeks)
2008 (8)	2 (1M/1F)	A=1 B=1	Severe (2)	NA	0/2	6.2/34 weeks	Amoxicillin+ Clavulanic acid: 2	Yes: 1 No: 1	Continuous: 1 Induction: 1	37 weeks/Stable while on therapy: 1
2008 (9)	2 (1M/1F)	A=1 B=1	Severe (2)	2/0	1/1	9.5/ NA	NA	Yes: 2	Continuous: 1 Induction: 1	NA/ Loss of response: 1 SAE: 1
2008 (2)	7 (4M/3F)	A = 1 B=6	Severe (7)	3/4	3/4	9.4/58.6 weeks	Methotrexate: 7	Yes: 7	Induction: 1 Continuous: 6	119 weeks/ Loss response: 2 Stable disease: 4 SAE: 1
Total single cases (1–10)	11 (7M/4F)	A=6 B=5	Severe (7), NA (4)	NA	11/0	4.6/36.4 weeks	Azathioprine: 2, Methotrexate: 2	Yes: 9 No: 2	Induction: 5 Continuous: 4 NA: 2	37.7 weeks/ Loss of response: 1, Recurrence: 1 (after 5 months) SAE: 2 NA: 2 Stable while on therapy: 3
2010 (11)	38 (12/26F) Infliximab treated patients: 33	NA, HSSI score	Severe (32), moderate (6) HSSI	NA	N.A	1: one infusions 8: <5 infusions 24: 5 infusions (22 weeks)	None	50% decrease HSSI week-8: 26.7% vs. 5% in placebo ($p=0.092$)	Induction and 2 maintanance infusions (24) Induction: 9	52 weeks (5): 2 sustained improvement, 3 relapse 30 weeks: 11 (outcome N.A) 22 weeks: 8 (outcome N.A) SAE: 6
Total	94 (39M/59F) NA: 1	A=22 B=28 NA=44	Moderate (8) Severe (82), NA (4)	15/4 NA: 75	20/18 NA: 56	4.94 infusions (66) NA: 38/24.63 weeks (67) NA: 37	Methotrexate: 9 Azathioprine: 2 Prednisone: 1 Cyclosporine: 1 Minocycline: 2 Amoxicillin+ Clavulanic acid: 2 No: 61 NA: 16	Evaluated in: 62: Yes: 52 No: 8 NA: 1	Induction: 44 Continuous: 48 NA: 2	53.79 weeks (48), NA: 46/ Loss of response: 8 SAE: 21 Recurrence: 15 Stable while on therapy: 4 Stable remission: 7 No response: 8 NA: 31
2008 (5)	1 (NE)	NE	NE	NE	NE	NE	NE	NE	NE	SAE: Fatal pneumococcal sepsis

*A ≤2 areas, B ≥3 areas.

NA: not available; NE: not evaluated (the article was not retrieved); HSSI: hidradenitis suppurativa severity index (5); SAE: severe adverse event that require suspension (Suspen.).

– Involved areas: axillae, groins, perianal, intergluteal and others (face, neck, anterior and posterior thorax, extremities).

Response during treatment was considered as: "yes" if there was a moderate to marked improvement and as "no" if there was a scarce or absent improvement. Improvement in HSSI score ≥ 50% was assessed as the primary endpoint of efficacy in one study (11).

– Severity was classified according to author's description. HSSI: HS severity index: moderate ≥ 8 and severe ≥ 13 (5).

– For specific co-morbidities details: see Table II.

– Induction therapy was defined as infusions administered at day-0, week-2 and week-6 or four or less infusions and continuous therapy was defined as more than four infusions.

– Outcome was classified as: stable while of therapy, stable remission (after withdrawal of infliximab), loss of response, recurrence, severe adverse event (SAE) and no response.

– Loss of response was defined as worsening of HS lesions during infliximab therapy.

– Recurrence was defined as worsening of HS lesion after suspension of infliximab therapy.

– Mean follow-up time was calculated when possible from the first day of infliximab therapy to the last date reported of follow-up.

[1]Sartorius Index see ref 16.